Cancer Research Technology Ltd

London, United Kingdom

Cancer Research Technology Ltd

London, United Kingdom

Time filter

Source Type

Patent
CANCER RESEARCH TECHNOLOGY Ltd | Date: 2017-01-12

The invention relates to the use of a binding member that binds to both SCR1 and SCR2 of CD55 in the treatment of tumours and leukaemia. The binding member may be an antibody that binds to SCR1 and SCR2 of CD55 and neutralizing CD55 and making cancer cells susceptible to complement-mediated attack.


Patent
Merck Patent GmbH and Cancer Research Technology Ltd | Date: 2017-02-01

The invention provides novel substituted pyridyl piperidine compounds according to Formula (I) which are Wnt pathway inhibitors, their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.


The present invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1 also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.


Patent
Astrazeneca and Cancer Research Technology Ltd | Date: 2017-04-05

The specification relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where Q, R, R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts.


Patent
Cancer Research Technology Ltd | Date: 2017-01-26

The present application provides a compound of formula (I) or a salt thereof, wherein R^(1), R^(2), R^(3), R^(4), R^(5), R^(6), A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.


Patent
Merck Patent GmbH and Cancer Research Technology Ltd. | Date: 2017-06-28

The invention provides novel substituted indazole compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or degenerative diseases.


Patent
Cancer Research Technology Ltd | Date: 2017-07-26

The invention provides compounds of formula (I) or a tautomer, stereoisomer, N-oxide, pharmaceutically acceptable salt or solvate thereof. The compounds are useful for the prophylaxis or treatment of a disease state or condition mediated by ERK5, in particular cancers.


Patent
Cancer Research Technology LLC | Date: 2017-04-24

The present disclosure provides pharmaceutical compositions comprising Gamma-glutamyl cycle inhibitors (GGCI) and certain pharmaceutically acceptable salts thereof, and methods of use.


Patent
Astex, The Institute Of Cancer Research Royal Cancer Hospital and Cancer Research Technology Ltd | Date: 2016-01-29

The invention provides compounds of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R^(1 )and NR^(2)R^(3 )and a maximum chain length of 4 atoms extending between E and NR^(2)R^(3), wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom with respect to the NR^(2)R^(3 )group and provided that the oxo group when present is located at a carbon atom with respect to the NR^(2)R^(3 )group;E is a monocyclic or bicyclic carbocyclic or heterocyclic group;R^(1 )is an aryl or heteroaryl group; andR^(2), R^(3), R^(4 )and R^(5 )are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.


Patent
CANCER RESEARCH TECHNOLOGY Ltd | Date: 2016-05-10

A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.

Loading Cancer Research Technology Ltd collaborators
Loading Cancer Research Technology Ltd collaborators